Summit Global Investments Makes New $232,000 Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Summit Global Investments purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 4th quarter, HoldingsChannel reports. The firm purchased 8,108 shares of the specialty pharmaceutical company’s stock, valued at approximately $232,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TD Private Client Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the last quarter. KBC Group NV lifted its position in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the period. Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical in the third quarter worth approximately $72,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after buying an additional 642 shares during the period.

Collegium Pharmaceutical Price Performance

COLL stock opened at $30.15 on Wednesday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29. The firm has a 50-day moving average of $30.57 and a 200 day moving average of $32.54. The company has a market cap of $949.30 million, a P/E ratio of 13.00 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent analyst reports. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.